Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT00052689
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 27
- Registration Number
- NCT00045695
- Locations
- 🇨🇦
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
🇺🇸Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇨🇦Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00027898
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00027716
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸University of Chicago Cancer Research Center, New York, New York, United States
Bortezomib in Treating Patients With Recurrent Glioma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00006773
- Locations
- 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States
PS-341 in Treating Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00025584
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT00052338
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT00028587
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
PS-341 in Treating Patients With Advanced Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-08-03
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT00006362
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
PS-341 in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00028639
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.